Inhibiting lysosomal aldolase: a magic bullet for AMPK activation in treating metabolic disease?  

作　　者：David Carling 

机构地区：[1]MRC London Institute of Medical Sciences,Imperial College,London W120NN,UK

出　　处：《Life Metabolism》2022年第3期209-210,共2页生命（代谢（英文）

摘　　要：In a tour-de-force study by Zhang et al.recently published in Nature Metabolism,a newly identified aldolase inhibitor,Aldometanib,is shown to activate lysosomal AMP-activated protein kinase(AMPK).Remarkably,mice treated with Aldometanib have increased insulin sensitivity,lowered blood glucose,and decreased hepatic steatosis and fibrosis,and are long-lived,effects of which all appear to be mediated via activation of lysosomal AMPK.AMPK is a central regulator of mammalian energy homeostasis,and activation of AMPK regulates a wide range of biological processes that are linked to multiple health benefits,associated with an increased healthy lifespan[1].Designing efficacious AMPK activators for clinical use that show long-term safety profiles has proved challenging,but the potential reward for such drugs would be substantial.

关 键 词：LYSOSOMAL HOMEOSTASIS drugs 

分 类 号：R589[医药卫生—内分泌]